ELISA/assay

Mouse Protectin ELISA Kit

MBS724150

48-Strip-Wells

470 USD

ELISA Kit

Mouse Protectin ELISA Kit

Protectin

CD59 glycoprotein preproprotein; CD59 glycoprotein; CD59 glycoprotein; protectin; 1F5 antigen; MEM43 antigen; Ly-6-like protein; T cell-activating protein; human leukocyte antigen MIC11; lymphocytic antigen CD59/MEM43; 20 kDa homologous restriction factor; membrane inhibitor of reactive lysis; membrane attack complex inhibition factor; membrane attack complex (MAC) inhibition factor; surface anitgen recognized by monoclonal antibody 16.3A5; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); CD59 molecule, complement regulatory protein; 1F5 antigen; 20 kDa homologous restriction factor; HRF-20; HRF20; MAC-inhibitory protein; MAC-IP; MEM43 antigen; Membrane attack complex inhibition factor; MACIF; Membrane inhibitor of reactive lysis; MIRL; Protectin; CD_antigen: CD59

CD59

CD59; CD59; 1F5; EJ16; EJ30; EL32; G344; MIN1; MIN2; MIN3; MIRL; HRF20; MACIF; MEM43; MIC11; MSK21; 16.3A5; HRF-20; MAC-IP; p18-20; MIC11; MIN1; MIN2; MIN3; MSK21; HRF-20; HRF20; MAC-IP; MACIF; MIRL

CD59_HUMAN

Mouse

This assay has high sensitivity and excellent specificity for detection of PROT. No significant cross-reactivity or interference between PROT and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between PROT and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 1.0 pg/mL.

Intended Uses: This PROT ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Mouse PROT. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Immunology

Principle of the assay: PROT ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-PROT antibody and an PROT-HRP conjugate. The assay sample and buffer are incubated together with PROT-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the PROT concentration since PROT from samples and PROT-HRP conjugate compete for the anti-PROT antibody binding site. Since the number of sites is limited, as more sites are occupied by PROT from the sample, fewer sites are left to bind PROT-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The PROT concentration in each sample is interpolated from this standard curve.

42716299

NP_976076.1

NM_203331.2

14,177 Da

Arf6 Trafficking Events Pathway (137954); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Complement Cascade Pathway (106405); Hematopoietic Cell Lineage Pathway (83078); Hematopoietic Cell Lineage Pathway (489); Immune System Pathway (106386); Innate Immune System Pathway (106387); Regulation Of Complement Cascade Pathway (576254)

This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations in this gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified for this gene. [provided by RefSeq, Jul 2008]

CD59: Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase. Defects in CD59 are the cause of CD59 deficiency (CD59D). Protein type: Membrane protein, GPI anchor. Chromosomal Location of Human Ortholog: 11p13. Cellular Component: anchored to external side of plasma membrane; compact myelin; extracellular space; focal adhesion; cell surface; membrane; plasma membrane; extracellular region; sarcolemma; vesicle. Molecular Function: complement binding; protein binding. Biological Process: cell activation; cell surface receptor linked signal transduction; regulation of complement activation; negative regulation of activation of membrane attack complex; innate immune response; positive regulation of T cell proliferation; blood coagulation; negative regulation of apoptosis. Disease: Hemolytic Anemia, Cd59-mediated, With Or Without Immune-mediated Polyneuropathy

48-Strip-Wells

470 USD

96-Strip-Wells

675